X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Part 1 of AVIATION Trial met primary safety endpoint compared to placebo, for TERN-201, a highly selective, irreversible, covalent inhibitor of VAP-1, administered for 12 weeks to presumed NASH patients was generally well-tolerated with a similar incidence of adverse events.
Lead Product(s): TERN-201
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
The trial will evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of TERN-201 in patients with presumed non-cirrhotic NASH and a cT1 value of greater than 800ms.
Lead Product(s): TERN-201
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
Details:
Terns recently completed a Phase 1 clinical study of TERN-201, which demonstrated that single and multiple oral administrations of TERN-201 were well tolerated with no significant safety findings observed.
Lead Product(s): TERN-201
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
Results from single and multiple ascending dose cohorts demonstrate TERN-201 is generally safe and well tolerated and results in potent and sustained inhibition of plasma SSAO activity.
Lead Product(s): TERN-201
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TERN-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
The company will give an oral presentation reviewing Phase 1 data on TERN-201, its semicarbazide-sensitive amine oxidase (SSAO) inhibitor in development for NASH.
Lead Product(s): TERN-201
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2020
Details:
Data presented at nash-tag conference 2020 showed over 90% reduction in plasma SSAO activity after single dose administrations of TERN-201.
Lead Product(s): TERN-201
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
